Idioma:

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer

Azambuja, E. ; Durbecq, V. ; Rosa, D. D. ; Colozza, M. ; Larsimont, D. ; Piccart-Gebhart, M. ; Cardoso, F.

Annals of oncology, 2008-02, Vol.19 (2), p.223-232 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por

Enviar para

Título:
HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
Autor: Azambuja, E. ; Durbecq, V. ; Rosa, D. D. ; Colozza, M. ; Larsimont, D. ; Piccart-Gebhart, M. ; Cardoso, F.
Assuntos: Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; Breast Neoplasms - surgery ; Chemotherapy, Adjuvant ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Drug Resistance, Neoplasm ; ECD ; Female ; Gene Expression Regulation, Neoplastic ; Gynecology. Andrology. Obstetrics ; HER-2 overexpression ; Humans ; Immunohistochemistry ; Mammary gland diseases ; Mastectomy - methods ; Medical sciences ; Neoplasm Staging ; Paclitaxel - administration & dosage ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Prognosis ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; Risk Assessment ; Sensitivity and Specificity ; Survival Analysis ; taxane resistance ; Taxoids - administration & dosage ; Trastuzumab ; Treatment Outcome ; Tumors
É parte de: Annals of oncology, 2008-02, Vol.19 (2), p.223-232
Notas: istex:AFD49C424A1B29E28007BC22274E14207BC8D4BC
ark:/67375/HXZ-RTDC5VPV-P
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Breast cancer (BC) is the most common cancer in women and it is incurable when metastases are diagnosed. Taxanes, namely docetaxel and paclitaxel, are effective chemotherapeutic agents in the metastatic, neoadjuvant and adjuvant settings. HER-2 overexpression/amplification is detected in 25–30% of BCs and confers aggressive tumor behavior as well as resistance to some systemic treatments; nevertheless, its association with response to taxane-based chemotherapy is still unclear, with conflicting results in both in vitro and in vivo preclinical studies. This review will address the impact of HER-2 overexpression/amplification in BC patients treated with taxanes. Prospective, randomized trials incorporating important biological hypotheses are either ongoing or just closed, and their results will hopefully help to shed more light on this issue.
Editor: Oxford: Oxford University Press
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer

Azambuja, E. ; Durbecq, V. ; Rosa, D. D. ; Colozza, M. ; Larsimont, D. ; Piccart-Gebhart, M. ; Cardoso, F.

Oxford: Oxford University Press

Buscando em bases de dados remotas. Favor aguardar.